-
Gene Therapy Helps Reduce Medication and Ease Movement Symptoms in Phase I Study
April 4, 2019
… of California, San Francisco (UCSF) published results from a small study involving 15 people ranging in age from 40 to 70 with moderate Parkinson's disease. The …
-
Elucidating the Mechanism of Action of J3, A Neuroprotective Small Molecule Candidate to Treat Parkinson's Disease
… and/or proteins that can be modulated to protect cells from the toxicity of alpha-synuclein, providing new targets … If we refute our current hypothesis, we expect that data from the proposed studies will generate a modified, …
-
The Impact of Oligomerization on Alpha-Synuclein Toxicity
… a ranking scale for the different alpha-synuclein variants from a toxic to a nontoxic form. Relevance to … In PD the process of aggregation of alpha-synuclein from monomers via oligomeric intermediates into amyloid …
-
A Pore-Based Method to Sort and Characterize Human Embryonic Stem Cell-Derived Dopaminergic Neurons
… undifferentiated, and potentially oncogenic, stem cells from a heterogeneous hESC population by screening for … Further, we have demonstrated the collection of NCAM+ cells from a heterogenous population. Thus, we can use our …
-
Can the electrocardiogram be used to identify pre-motor Parkinson's Disease
… Description: We will evaluate the electrocardiograms from 47 patients diagnosed with pure RBD who underwent all … with insomnia will serve as controls. EKG recordings from RBD patients and control subjects will be downloaded …
-
The anatomic basis of cardiac and cognitive changes in Parkinson's disease: A collaborative study with the Parkinson's Institute, Sunnyvale, CA (USA)
… brain hemisphere sections and brainstem serial sections from 27 individuals with clinical evidence of dementia who … for early Parkinson’s disease. The findings gained from the pilot study can be used to establish …